# Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

> **NCT03911076** · PHASE2 · TERMINATED · sponsor: **PapiVax Biotech, Inc.** · enrollment: 16 (actual)

## Conditions studied

- ASC-US
- ASC-H
- LSIL

## Interventions

- **BIOLOGICAL:** PVX-2
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03911076
- **Lead sponsor:** PapiVax Biotech, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-22
- **Primary completion:** 2022-06-08
- **Final completion:** 2022-06-08
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Slow recruitment/funding
- **Last updated:** 2024-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03911076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03911076, "Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03911076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*